July 16, 2021 - July 20, 2021

Tatva Chintan Pharma IPO Review & Recommendations

Dilip Davda, Investmentz Ltd, KR Choksey Securities Ltd, Motilal Oswal, Reliance Securities, InvestorGain.com and Ventura Securities Limited have given "Apply" recommendation to Tatva Chintan Pharma IPO. Capital Market has given "May Apply" recommendation to Tatva Chintan Pharma IPO. Axis Capital and Sharekhan Limited have "Neutral" view about the IPO.

Tatva Chintan Pharma IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	7	1	2	0	0
%	70.00	10.00	20.00	0.00	0.00

Tatva Chintan Pharma IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Axis Capital	Neutral
Capital Market	May Apply
Dilip Davda	Apply
Investmentz Ltd	Apply
KR Choksey Securities Ltd	Apply
Motilal Oswal	Apply
Reliance Securities	Apply
Sharekhan Limited	Neutral
InvestorGain.com	Apply
Ventura Securities Limited	Apply

Tatva Chintan Pharma IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Tatva Chintan Pharma IPO is 50. Their analysis recommends May subscribe for the IPO.

Reviewer	Rating Score	Rating
Capital Market	50	May subscribe

Tatva Chintan Pharma IPO Review by Dilip Davda (Apply)

[Dilip Davda] The company is in a fast forward mode and the issue is reasonably priced. The green chemical industry is fancied by investors across the board. Investment may be considered for short to long term rewards. Read detail review...

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.